# Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

> **NCT00759655** · PHASE3 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Moroctocog alfa

## Key facts

- **NCT ID:** NCT00759655
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759655, "Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00759655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*